Stifel lowered the firm’s price target on Nkarta (NKTX) to $11 from $12 and keeps a Buy rating on the shares. The firm believes management’s decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
- Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
- Nkarta Advances NKX019 Program Amid Financial Stability
- Nkarta reports Q3 EPS (29c), consensus (30c)
- Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
- Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases